Review
doi: 10.1016/j.jneuroim.2011.01.009.
Epub 2011 Mar 13.
Recent insights into the mechanism of action of glatiramer acetate
Affiliations
- PMID: 21402415
- DOI: 10.1016/j.jneuroim.2011.01.009
Item in Clipboard
Review
Recent insights into the mechanism of action of glatiramer acetate
J Neuroimmunol.
2011 Jun.
Abstract
Glatiramer acetate (GA, Copaxone®, co-polymer 1) is an immunomodulatory therapy approved in 1996 by the United States Food and Drug Administration for treatment of relapsing-remitting multiple sclerosis. GA has a good safety profile, moderate efficacy, and a unique mode of action. Recent evidence in an animal model of MS, experimental autoimmune encephalomyelitis (EAE), suggests that GA effects on NK cells and B cells may contribute to therapeutic efficacy. We review the mechanism of action of GA, with particular focus on recent data suggesting a role for regulatory B cells.
Copyright © 2011 Elsevier B.V. All rights reserved.
Similar articles
-
B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.Exp Neurol. 2010 Jan;221(1):136-45. doi: 10.1016/j.expneurol.2009.10.015. Epub 2009 Oct 29. Exp Neurol. 2010. PMID: 19879259
-
The use of glatiramer acetate in the treatment of multiple sclerosis.Adv Neurol. 2006;98:273-92. Adv Neurol. 2006. PMID: 16400839 Review.
-
Glatiramer acetate: mechanisms of action in multiple sclerosis.Int Rev Neurobiol. 2007;79:537-70. doi: 10.1016/S0074-7742(07)79024-4. Int Rev Neurobiol. 2007. PMID: 17531858 Review.
-
Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.J Neurol Sci. 2009 Dec;287 Suppl 1:S17-23. doi: 10.1016/S0022-510X(09)71296-1. J Neurol Sci. 2009. PMID: 20106343
-
Glatiramer acetate: mechanisms of action in multiple sclerosis.Autoimmun Rev. 2007 Aug;6(7):469-75. doi: 10.1016/j.autrev.2007.02.003. Epub 2007 Mar 6. Autoimmun Rev. 2007. PMID: 17643935 Review.
Cited by
-
What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?Int J Mol Sci. 2012 Oct 4;13(10):12665-709. doi: 10.3390/ijms131012665. Int J Mol Sci. 2012. PMID: 23202920 Free PMC article. Review.
-
Transcriptional Regulation of Brain-Derived Neurotrophic Factor (BDNF) by Methyl CpG Binding Protein 2 (MeCP2): a Novel Mechanism for Re-Myelination and/or Myelin Repair Involved in the Treatment of Multiple Sclerosis (MS).Mol Neurobiol. 2016 Mar;53(2):1092-1107. doi: 10.1007/s12035-014-9074-1. Epub 2015 Jan 13. Mol Neurobiol. 2016. PMID: 25579386 Review.
-
Role of Tumor Necrosis Factor Superfamily in Neuroinflammation and Autoimmunity.Front Immunol. 2015 Jul 20;6:364. doi: 10.3389/fimmu.2015.00364. eCollection 2015. Front Immunol. 2015. PMID: 26257732 Free PMC article. Review.
-
Glatiramer acetate does not protect from acute ischemic stroke in mice.Exp Transl Stroke Med. 2014 Feb 27;6(1):4. doi: 10.1186/2040-7378-6-4. Exp Transl Stroke Med. 2014. PMID: 24576335 Free PMC article.
-
Synthetic Cationic Autoantigen Mimics Glatiramer Acetate Persistence at the Site of Injection and Is Efficacious Against Experimental Autoimmune Encephalomyelitis.Front Immunol. 2021 Jan 18;11:603029. doi: 10.3389/fimmu.2020.603029. eCollection 2020. Front Immunol. 2021. PMID: 33537031 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
